At the end of 2012, Ian Boulton was asked to present on malaria diagnosis in the private retail sector at the 11th Assises Panafricaines de Lutte Contre le Paludisme (11th Pan-African National Malaria Control Programmes Meeting), sponsored and organised Sanofi, under the title:- Mise à disposition des TDR dans le marché privé dans un contexte de T3; faisabilité, risques et opportunités? (Availability of RDTs in the private market within the context of T3, feasibility challenges and opportunities) This presentation built upon TMPC’s work on the Affordable Medicines Facility – malaria (AMFm) and the need to extend the use of diagnosis of malaria into the private market. This was also in the context of the launch of the World Health Organization’s “Test: Treat: Track” strategy for malaria.
About TMPCThis author has not yet filled in any details.
So far TMPC has created 18 blog entries.
At the end of 2012, Ian Boulton was asked to present his views on the results of the Affordable Medicines Facility – malaria (AMFm) at the 11th Assises Panafricaines de Lutte Contre le Paludisme (11th Pan-African National Malaria Control Programmes Meeting), sponsored and organised Sanofi, under the title:- Le devenir de l’AMFm: Bilan de la phase 1 et perspective – le modè le AMFm est – il viable sans les sources actuelles de financement? (The Future of AMFm: The Results of Phase 1 and Future Prospects – is the model viable without the current funding?)
The Affordable Medicines Facility – malaria (AMFm) was an initiative piloted in Africa. Its main objective was to increase access to Quality Assured Artemisinin-containing Combination Treatments (QAACTs) through a co-payment mechanism. The co-payment was intended to reduce the end-user price of QAACTS to the same level as chloroquine or sulphadoxine-pyrimethamine. The pilot programmes ended in December 2012 and the Global Fund asked the Roll Back Malaria Partnership (RBM) to take leadership in planning for the transition in 2013 to the next phase of this initiative. The RBM Board discussed this issue at its May 2012 meeting.
In May 2011, the African Leaders’ Malaria Alliance (ALMA), the Global Fund, the Medicines for Malaria Venture (MMV), and the Roll Back Malaria Partnership sponsored a Forum for Africa-based Pharmaceutical Manufacturers and Potential Investors in Nairobi. It aimed to bring together manufacturers and potential investors or technical collaborators and facilitate communication between them, with the aim of stimulating the development of a world class pharmaceutical manufacturing industry in Africa.
“The Coordination, Rationalization, and Integration of anti-MALarial drug Discovery & Development Initiatives (CRIMALDDI) Consortium, funded by the EU Framework Seven Programme, attempted in 2009-2010, through a series of interactive and facilitated workshops, to develop priorities for research to expedite the discovery of new anti-malarials...
Following the Roll Back Malaria Partnership (RBM) Change Initiative in 2006 and the quadrennial External Evaluation in 2009, the RBM Board established a Task Force to develop an Accountability Framework to guide the work and responsibilities of all the RBM Partners. TropMed Pharma Consulting was retained as the consultant to the Task Force.
In December 2008, Ian Boulton was asked to present on “A Private Sector Perspective” at an Academy of Medical Sciences Conference Global Health Diagnostics: Research, Development, & Regulation. Founded in 1998, the Academy of Medical Sciences is the independent body in the UK that represents the diverse spectrum of medical science – from basic research through clinical application to healthcare delivery.
In 2006, the Dutch Ministry of Foreign Affairs, the European & Developing Countries Clinical Trials Partnership (EDCTP), and the Netherlands-African partnership for Capacity development and Clinical interventions Against Poverty-related diseases (NACCAP) organised a Stakeholder Forum on the challenges of treating poverty-related diseases. It brought together representatives from academia, industry, governments and non-governmental organisations to debate: “Connecting the Chain: Towards a comprehensive approach to delivering affordable medicines against poverty-related diseases”.